Structural margin
An India manufacturing base serving global premium price points — the core economic engine of the business.
Investor relations
A rare moment in a proven category.
Premium wellness is one of the most active categories in the market — and it is consolidating around brands with genuine, defensible differentiation. RX Superceuticals is built precisely for that: an Indian cost base, global premium positioning, owned intellectual property, and a clinical programme that turns claims into evidence.
The investment thesis
Made in India. Priced for the world.
Our advantage is structural. We manufacture at India's genuine cost base and sell into premium markets that value — and pay for — quality, transparency and proof. It is a model designed for both strong unit economics and a durable, defensible brand.
Owned IP
A trademarked brand and a patent-pending delivery system — differentiation we own, not a platform we rent.
Clinical evidence
A finished-product clinical trial underway — a standard of proof rare in the category and difficult to copy.
An active market
Premium wellness is consolidating, with strategic acquirers actively seeking differentiated, evidence-led brands.
What we are building
A brand engineered to lead — and to be acquired-grade.
We are building RX to be the premium, clinically-validated, globally-scalable nutraceutical brand the Indian market has not yet produced — and to be exactly the kind of asset the current wave of acquirers is looking for.
We are currently raising a growth round to launch across our first markets, complete our clinical programme, and secure our intellectual property. Detailed financials, projections, and terms are shared privately with qualified investors under confidentiality.
RX-IR · At a glance
- StageGrowth round
- Use of fundsLaunch · trial · IP
- First marketsIndia & UAE, then USA
- ModelPremium D2C, subscription
- MaterialsOn request, under NDA
Financial details provided to qualified investors only.
Get in touch
Request the confidential investor pack.
Qualified investors, prospective retail and distribution partners, and media are welcome to reach out. Tell us who you are and what you are looking for, and the right person will respond.
Email · anshuman@rxsuperceuticals.com
Phone · +91 77385 87777
Entity · RX Superceuticals Private Limited
CIN · U21001PN2024PTC234633
Registered office · Unit 101, Wing R, Marvel Zephyr, Kharadi, Pune, Maharashtra 411014, India
GSTIN & FSSAI licence no. — to be displayed here before retail sale in India
Phone · +91 77385 87777
Entity · RX Superceuticals Private Limited
CIN · U21001PN2024PTC234633
Registered office · Unit 101, Wing R, Marvel Zephyr, Kharadi, Pune, Maharashtra 411014, India
GSTIN & FSSAI licence no. — to be displayed here before retail sale in India